Skip to content

Trial Objectives

Researchers want to know if a new medication, Saracatinib, is a more safe and effective treatment for Idiopathic Pulmonary Fibrosis (IPF) when compared to treatments that are currently available. 

Who Can Participate

Adults 40 years of age and older.

Age: 40+ Gender Any

Estimated Time Commitment

Not Specified

Time Commitment Details

Visits will take two to four hours.

Payment & Reimbursement

Payment Not Provided

Travel Reimbursement Not Available

Trial Contact

For more information, contact:

Kaitlin Fier

Request More Information

Trial Location

National Jewish Main Campus, Denver, CO

Trial Sponsors

National Institutes of Health

Principal Investigators

Gregory P. Downey

Gregory P. Downey, MD


Kevin K. Brown

Kevin K. Brown, MD

Request more Information

By completing this form, you agree to learn more about this study and see if you qualify.

I would also like to receive periodic emails with health information, news and clinical research updates from National Jewish Health required